secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2024-01-09T23:59:59+00:00
Accession:  0000950170-24-003197
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 3.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus receives FDA IND clearance for CRB-601; Nasdaq grants extension to May 8, 2024
--------------------------------------------------------------------------------

- FDA cleared IND for CRB-601, a TGFβ blocking monoclonal antibody targeting integrin αvβ8.
- Phase 1 study first participant enrollment expected in H1 2024; pre-clinical data showed enhanced anti-tumor activity.
- Nasdaq granted extension until May 8, 2024 to regain compliance with $2.5M stockholders' equity requirement, conditional on capital raise.
- Stockholders' equity was $311,016 as of Sep 30, 2023, below the $2.5M minimum; alternative standards not met.
- Failure to regain compliance by May 8, 2024 may lead to delisting; company has right to appeal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000095017024003197/0000950170-24-003197-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000095017024003197/crbp-20240108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-003197

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer